Immune restoration and HAART: New clinical and in vitro data

AIDS Reader

Volumn 12, Issue 10, 2002, Pages 421-422

  Laurence, Jeffrey ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

HAART; HIV AIDS; Immune restoration; Infection, opportunistic; Sexually transmitted diseases

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; TUBERCULOSTATIC AGENT;

DRUG EFFICACY; EDITORIAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOREACTIVITY; INFECTION RESISTANCE; LYMPHOCYTE COUNT; OPPORTUNISTIC INFECTION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; GOALS; HEALTH PROMOTION; HIV INFECTIONS; HUMANS; IMMUNE SYSTEM; IMMUNOSUPPRESSION;

EID: 0036797187     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (9)

1. Healthy Cities, Healthy Suburbs: Progress in Meeting Healthy People Goals for the Nation's 100 Largest Cities & Their Suburbs. Princeton, NJ: Robert Wood Johnson Foundafion; August 2002.
2. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119-129.
3. Kirk O, Reiss P, Uberti-Foppa C, et al. Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. Ann Intern Med. 2002;137:239-250.
4. Kaplan JE, Masur H, Holmes KK. Discontinuing prophylaxis against recurrent opportunistic infections in HIV-infected persons: a victory in the era of HAART Ann Intern Med. 2002;137:285-287.
5. Furrer H, Opravil M, Rossi M, et al. Discontinuation of primary prophylaxis in HIV-infected patients at high risk of Pneumocystis carinii pneumonia: prospective multicentre study. AIDS. 2001;15:501-507.
6. Ledergerber B, Mocroft A, Reiss P, et al. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups. N Engl J Med. 2001;344:168-174.
7. Lange CG, Lederman MM, Madero JS, et al. Impact of suppression of viral replication by highly active antiretroviral therapy on immune function and phenotype in chronic HIV-1 infection. J Acquir Immune Defic Syndr. 2002;30:33-40.
8. Mussini C, Pinti M, Borghi V, et al. Features of 'CD4-exploders,' HIV-positive patients with an optimal immune reconstitution after potent antiretroviral therapy. AIDS. 2002;16:1609-1616.
9. -T cells spëcific for tuberculosis correlate with improved clinical immunity after highly active anti-retroviral therapy. AIDS Res Hum Retroviruses. 2002;18:969-975.